Bristol Myers Squibb: Still Cheap, Despite What The Chart Says

Bristol Myers Squibb (BMY) is reiterated as a Strong Buy, trading ~51% below the sector median, supported by a defensive setup. Its growth portfolio delivered 15% YoY revenue growth, offsetting Opdivo decline headwinds and the risk from an upcoming Eliquis patent expiry, while the stock offers a 3.7% forward dividend yield. The note highlights robust margins and accelerating bottom-line growth, improving the risk/reward profile despite near-term patent uncertainty.

Analysis

The market is effectively pricing BMY as a patent-cliff story first and a growth story second. That creates an attractive setup only if the newer portfolio can keep compounding fast enough to absorb the next leg of LOE without a margin reset; otherwise the stock stays trapped at a low multiple and the dividend just becomes a value trap. The key second-order effect is portfolio rotation: if investors start believing earnings are more durable, BMY can attract defensive-income capital that has been sitting in higher-yield, lower-quality healthcare names, forcing multiple re-rating without needing huge top-line surprise.

Near term, the main catalyst path is not absolute revenue growth but the quality of the revenue bridge into the patent expiry window: gross margin resilience, buyback pace, and whether management can keep guidance from drifting down as the cliff approaches. Over 1-3 months, any evidence that the growth portfolio is scaling faster than the market expects should matter more than headline EPS; over 6-18 months, the debate becomes whether BMY deserves to trade like a cash-generative compounder versus a melting-ice-cube pharma name. The contrarian risk is that the discount is not cheap if consensus is still underestimating the drag from LOE and pipeline execution risk.

This is a better relative-value trade than an outright momentum buy. A clean expression is long BMY vs short PFE on valuation and capital-return support, since both face patent/portfolio questions but BMY appears better positioned to defend cash generation; use the pair only if the next earnings print confirms stable margins and a credible post-expiry bridge. If the stock sells off into results, a small starter long with a 6-12 month horizon offers asymmetric downside protection from the dividend, but the thesis should be falsified if management lowers the medium-term revenue outlook or if the growth portfolio decelerates below low-to-mid single digits.

Key Decisions for Investors

• Initiate a modest long BMY position on any post-earnings weakness; target a 10-15% rerating over 6-12 months if management sustains margin and buyback discipline.
• Pair trade: long BMY / short PFE over 1-3 months to isolate relative cash-flow durability and dividend-supported multiple support; cover if PFE guidance inflects positively or BMY revenue bridge weakens.
• Set an alert on the next earnings call for the post-patent-expiry revenue bridge and free-cash-flow conversion; if consensus forward revenue is cut or gross margin compresses materially, abandon the long.
• For income-oriented books, use BMY as a defensive healthcare allocation versus XBI, since the stock’s downside is better buffered by capital returns than most biotech exposures.